drugset / Trial / NCT05830799
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
NaSingle-groupOpen-labelBasic science
Summary
This is a single-centre, open-label, fixed-sequence trial to evaluate the impact of C21 on the exposure of CYP1A2, CYP2C9, CYP3A4 and P-gp substrates in healthy volunteers.
Timeline
- Start
- 2023-03-29
- Primary completion
- 2023-05-11
- Completion
- 2023-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C21 | Unknown | — | Oral |
| Subject | Caffeine | Small molecule | — | — |
| Subject | Midazolam | Small molecule | — | — |
| Subject | Nintedanib | Small molecule | — | — |
| Subject | Tolbutamide | Small molecule | — | — |
Indications
No indication recorded.